Gain Therapeutics Balance Sheet Health
Financial Health criteria checks 4/6
Gain Therapeutics has a total shareholder equity of $8.9M and total debt of $494.4K, which brings its debt-to-equity ratio to 5.5%. Its total assets and total liabilities are $14.4M and $5.5M respectively.
Key information
5.5%
Debt to equity ratio
US$494.41k
Debt
| Interest coverage ratio | n/a |
| Cash | US$12.05m |
| Equity | US$8.91m |
| Total liabilities | US$5.46m |
| Total assets | US$14.37m |
Recent financial health updates
Recent updates
Gain Therapeutics: Phase 1 Readout Awaits For Parkinson's Drug With Great Potential
May 29Gain Therapeutics: The Case For GCase In Parkinson's And Buyout Potential
Jan 12Gain Therapeutics appoints CEO
Sep 20Gain Therapeutics: Shares Of Enzyme Therapy/Neurodegeneration Specialist Look Like A Surprisingly Good Value
Oct 27Gain Therapeutics: A True Revolution In Drug Development At Venture-Like Pricing
Aug 19Gain Therapeutics EPS misses by $0.29
May 10Financial Position Analysis
Short Term Liabilities: GANX's short term assets ($13.7M) exceed its short term liabilities ($4.6M).
Long Term Liabilities: GANX's short term assets ($13.7M) exceed its long term liabilities ($861.5K).
Debt to Equity History and Analysis
Debt Level: GANX has more cash than its total debt.
Reducing Debt: GANX had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GANX has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: GANX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 33.7% each year
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/29 07:56 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Gain Therapeutics, Inc. is covered by 8 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Thomas Shrader | BTIG |
| Keay Nakae | Chardan Capital Markets, LLC |